Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 830

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Hoe 140 a new potent and long acting bradykinin‐antagonist:in vivo studies

Open access
Wirth, K., Hock, F.J., Albus, U., Linz, W., Alpermann, H.G., Anagnostopoulos, H., Henke, St., Breipohl, G., König, W., Knolle, J., Schölkens, B.A.·1991·British Journal of Pharmacology

Abstract

The potency, duration of action and tolerability of Hoe 140, a novel and highly potent bradykinin (BK) antagonist in vitro, has been tested in different in vivo models and compared with the well‐known BK antagonist d‐Arg‐[Hyp 2, Thi 5,8,d‐Phe 7]BK. Hoe 140 is highly potent and long acting in inhibiting BK‐induced hypotensive responses in the rat. Four hours after s.c. administration of 20 nmol kg−1, inhibition still amounted to 60% whereas the effect of 200 nmol kg−1 of d‐Arg‐[Hyp 2, Thi 5,8,d‐Phe 7]BK was not significant. BK‐induced bronchoconstriction in guinea‐pigs was strongly inhibited by Hoe 140. The magnitude and duration of inhibition confirmed the findings obtained in the blood pressure experiments in the rat. Carrageenin‐induced inflammatory oedema of the rat paw was considerably inhibited at i.v. doses between 0.1 and 1 mg kg−1. In conscious dogs, intravenous doses of 0.01 and 0.1 mg kg−1 of Hoe 140 and d‐Arg‐[Hyp 2, Thi 5,8,d‐Phe 7]BK were well tolerated. At doses of 1 mg kg−1 adverse effects occurred that were attributed to the residual BK agonistic activity of both compounds. Hoe 140 has been shown to be a highly potent and long acting BK antagonist in vivo in different animal species and models. This makes it appropriate to investigate further the physiological and pathophysiological role of BK.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.1991.tb12249.x

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 830

Metadata

Authors
Wirth, K., Hock, F. J., Albus, U., Linz, W., Alpermann, H. G., Anagnostopoulos, H., Henke, S., Breipohl, G., König, W., Knolle, J., & Schölkens, B. A.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
1991-03
Volume
102
Issue
3
Pages
774-777
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1974146850
Cited by
830
References
19
FWCI
43.11
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hoe 140 a new potent and long acting bradykinin‐antagonist:in vivo studies. https://app.cochat.ai/papers/10.1111/j.1476-5381.1991.tb12249.x
The paper
Wirth, K., Hock, F. J., Albus, U., Linz, W., Alpermann, H. G., Anagnostopoulos, H., Henke, S., Breipohl, G., König, W., Knolle, J., & Schölkens, B. A. (1991). Hoe 140 a new potent and long acting bradykinin‐antagonist:in vivo studies. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.1991.tb12249.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.